Takeda Official Says Alogliptin Faces Near Three-Year U.S. Delay
This article was originally published in PharmAsia News
Takeda Pharmaceutical said a launch of its SYR-322 alogliptin diabetes drug would be delayed by nearly three years after U.S. FDA ordered new trials as a condition for approval. The agency told Takeda in March it would need more data on the drug, leading Takeda earlier this month to delay its plans to seek European approval until 2012. A Takeda public relations executive acknowledged the need to conduct more tests would delay U.S. approval until at least the end of the March, 2012, business year. (Click here for more
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.